DWA
TCRR

Dorsey Wright & Associates’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Dorsey Wright & Associates’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-565
Closed -$17K – 388
2020
Q4 		$17K Buy
565
+141
+33% +$3.56K ﹤0.01% 202
2020
Q3 		$9K Buy
+424
New +$7.45K ﹤0.01% 222

Other funds holding TCRR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Dorsey Wright & Associates's TCRR Position: Q1 2021 in Review

Dorsey Wright & Associates sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2021, closing a stake of 565 shares — an estimated $17K sold.

Dorsey Wright & Associates first reported a position in TCRR in Q3 2020 and held it in 2 quarters. The position peaked at $17K in Q4 2020. 129 funds tracked by Wall St. Rank hold TCRR as of Q1 2021.

  • Dorsey Wright & Associates reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Dorsey Wright & Associates sold 565 TCR2 Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $17K.
  • Dorsey Wright & Associates first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Dorsey Wright & Associates's TCR2 Therapeutics Inc. Common Stock position peaked at $17K in Q4 2020.
  • 129 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2021.

Based on Dorsey Wright & Associates's 13F filing for Q1 2021, filed 27 Apr 2021.